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Abstract
Purpose: To assess the cross-sectional construct validity of the Health Utilities Index Mark 3 (HUI3) in lung
transplantation.
Methods: Two hundred and thirteen patients (103 pre-transplant and 110 post-transplant) with mean age 53 years
old (SD 13) were recruited during a randomized controlled clinical trial at the out-patient clinic in a tertiary
institution. At baseline, patients self-completed measures that included the HUI3, EuroQol EQ-5D, Hospital Anxiety
and Depression Scale (HADS) and socio-demographic questionnaire. Six-minute walk test scores and forced
expiratory volume in 1 second data were collected from patient’s medical records. A priori hypotheses were
formulated by members of the transplant team about the expected degree of association between the measures.
Correlation coefficients of < 0.1 were considered as negligible, 0.1 to < 0.3 as small, 0.3 to < 0.5 as medium, and ≥0.5
as large.
Results: Of the ninety predictions made, forty three were correct but in 31 the correlation was slightly lower than
predicted and in 7 the correlations were much higher than predicted. In 48% of the cases, predicted and observed
associations were in agreement. Predictions of associations were off by one category in 42% of the cases; in 10%
of the cases the predictions were off by two categories.
Conclusions: This is the first study providing evidence of cross-sectional construct validity of HUI3 in lung
transplantation. Results indicate that the HUI3 was able to capture the burden of lung disease before transplantation
and that post-transplant patients enjoyed higher health-related quality of life than pre-transplant patients.
Background
The major end-points in lung transplantation are survi-
val and health-related quality of life (HRQL). HRQL
assessments are important for understanding the impact
of treatment on patients, including physical functioning
and emotional well-being. Recent studies shown that
after transplantation the most significant improvements
were reported in physical and social functioning, and
overall HRQL [1-10], whereas psychological problems
seemed to be prevalent after the transplant [2,10]. In
lung transplantation, the most commonly used measures
are health profiles, like the SF-36 [11]. Health profiles
do not incorporate values/preference information which
requires such data for the estimation of quality-adjusted
life years (QALY). As a result health profiles measures
are not suitable for use in economic evaluations com-
paring the cost-effectiveness of different treatments and
interventions.
In lung transplantation, the determination of relative
benefits and costs of different treatments and interven-
tions are of importance to clinical care optimization.
Therefore, recently studies have incorporated preference-
based measures [6,10,12,13]. There are two types of prefer-
ence-based measures: direct and multi-attribute. Direct
measures, visual analog scales (VAS), time trade-off
(TTO) and standard gamble (SG) assess the preference for
* Correspondence: msantana@ualberta.ca
1Lung Transplant Program. 2E4.31 Walter C. Mackenzie Health Sciences
Centre. University of Alberta Hospital. Edmonton. T6G2B7, Alberta, Canada
Full list of author information is available at the end of the article
Santana et al. Health and Quality of Life Outcomes 2010, 8:110
http://www.hqlo.com/content/8/1/110
© 2010 Santana et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.a health state and are suitable for specific purposes allow-
ing the researcher to incorporate items that are more rele-
vant to a particular population. Multi-attribute preference
measures, such as Health Utilities Index Mark 2 (HUI2)
[14] and Mark 3 (HUI3) [15], EuroQol (EQ-5D) [16],
SF-6D [17] and Quality of Wellbeing questionnaire
(QWB) [18], describe the health status of a subject using a
multi-attribute classification system and use a scoring
system to value health status.
Compared with other multi-attribute preference mea-
sures, the HUI3 was selected for several reasons. First,
the SF-6D [17] has floor effects. The QWB [18] scale is
lengthy, increasing the burden to patients. The HUI3 has
more breadth and depth (HUI3 includes 8 attributes with
5 to 6 levels in each) than the EQ-5D [16] (includes 5
attributes with 3 levels in each) providing more detailed
information on the patient’s health status for clinicians.
The EQ-5D has ceiling-effect problems and often misses
health states with mild burdens. Lung transplant recipi-
ents are fairly close to population norms and typically
experience states with mild burdens. The EQ-5D has the
potential to misinterpret health status because it does not
include levels for mild problems, as seen in the gap in the
scores between 0.88 and 1.00 (perfect health). Thus, EQ-
5D may identify a patient as experiencing perfect health
when in reality that patient is experiencing a health state
with a mild burden.
HUI3 provides detailed information about patient’s
health status by including an overall score and single-
attribute utility scores. The HUI3 includes eight attri-
butes (vision, hearing, speech, ambulation, dexterity,
cognition, emotion, pain and discomfort) with five or six
levels for each attribute [14,15,19]. The single-attribute
utility scores convey information about the degree of
disability in each attribute. Furthermore, HUI3 [15] is
useful because describes a great number of health states,
and captures the severity of the disease and burden of
side-effects associated with drugs and other treatments,
and the burdens associated with comorbidities. For
instance, symptoms such as fatigue and breathing limita-
tions will limit ambulation. Also, changes in emotional
states due to some treatments may be present in some
patients and captured by HUI3 emotion. Pain will limit
patients’ ambulation and health status.
The HUI3 has been used in population health surveys in
Canada since 1990 [20]. The validity of the HUI3 has been
demonstrated for various diseases as well as the general
population [21-32]. Recently, the HUI3 has been used in
lung transplantation [10,33]. Santana et al [10] using the
HUI3 followed prospectively 43 pre-transplant patients
after six months post-transplantation. In this study the
HUI3 was able to detect improvement after transplant.
However, the present study is the first to add evidence on
the cross-sectional construct validity of the HUI3 in lung
transplantation. We examined convergent validity, diver-
gent validity and the known-groups approach.
Construct validity is an important component in the
evaluation of the performance of HRQL measures. The
assessment of construct validity is an on-going exercise
that requires the accumulation of evidence about the
performance of a measure in different settings. One way
to assess construct validity is the extent to which a par-
ticular measure relates to other measures in a way that
is consistent with theoretically derived hypotheses
related to the concepts that are being measured. Thus,
measures are valid when they measure what they are
supposed to measure [34,35]. And measures are respon-
sive when they are able to capture meaningful change
over time. Convergent validity considers the direction
and degree of association that one expects to observe
among measures of the same or a similar construct. For
example ambulation scores would be highly related to
and systematically vary with six-minute walk test scores.
In contrast for discriminative validity one examines the
degree of association when little or no association
among the constructs is expected. For instance, ambula-
tion scores are not expected to be highly related to
patient’s marital status. Known-groups comparison is
another approach for assessing construct validity. One
anticipates that specific groups of patients will score dif-
ferently from others, thus the measure should be sensi-
tive to these differences. On the basis of independent
evidence based on clinical measures, we would expect
that HUI3 would discriminate between pre- and post-
transplant patients.
Methods
Patients and Procedure
The patient sample included pre-lung transplant (sub-
jects who were included on the waiting list and were
being seen at the out-patient clinic) and post-lung trans-
plant subjects. Patients were excluded if they were
younger than 18 years of age, diagnosed as being cogni-
tively impaired, or unable to complete questionnaires in
English.
The main study was a randomized controlled clinical
trial that assessed the effect of using HRQL measures in
routine clinical care of lung transplant patients [33].
The study was conducted at the lung transplant
out-patient clinic, at the University of Alberta Hospital,
Edmonton. The out-patient lung transplant team con-
sisted of three physicians, two nurses, one pharmacist,
and one dietician. Ethics approval was obtained from
the Health Research Ethics Panel B, file # 101004,
University of Alberta.
Baseline data was collected at the first patient visit
once patient consent had been obtained. At baseline,
patients self-completed a battery of paper-and-pencil
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Depression Scale (HADS), Health Utilities Index Mark 3
(HUI3), and EQ-5D. Pulmonary function test was con-
ducted at the pulmonary laboratory and the six-minute
walk test (6MWT) was performed at the Physiotherapy
Department.
Health Status and Health-related Quality of Life Measures
Health Utilities Index Mark 3, HUI3
The 15-item HUI self-assessment self-complete one-
week recall questionnaire was used in the study. The
levels range from severe disability (e.g., so unhappy that
life was not worthwhile) to no disability (e.g., happy and
interested in life) [15,19]. HUI3 describes a total of
972,000 unique health states. An individual health status
is described by an eight-element vector, with one level
for each attribute. The HUI3 scoring function is a multi-
plicative multi-attribute that was developed based on
community preferences obtained from a random sample
of the Canadian population [15]. The HUI3 single-attri-
bute utility scores (SAUS) are on a scale in which the
score for most highly impaired level is 0.00 and the
score for normal is 1.00. HUI3 overall scores are on a
scale in which the all-worst HUI3 state (every attribute
is at its highest level of disability) has a score of -0.36
(negative scores reflect health states considered by to be
worse than being dead), dead is 0.00 and perfect health
is 1.00. Changes of 0.03 or more in overall HUI scores
and 0.05 or more in single-attribute scores are consid-
ered clinically important [19].
Euroqol, EQ-5D
EQ-5D, a brief generic preference-based measure that
consists of two components: a 100-point visual analog
scale (VAS) and a descriptive system [16]. The 20 cm
VAS ranges from 0 (worst imaginable health) to 100
(best imaginable health). Patients are asked to rate their
o w nh e a l t ht h a td a yb yd r a w i n gal i n ef r o mab o xt oa
point on the VAS. The descriptive or self-classification
system contains five attributes (mobility, self-care, usual
activities, pain or discomfort, and anxiety or depression)
with three levels per attribute ("no problem”, “some pro-
blems” and “extreme problems”). The EQ-5D classifica-
tion system generates 243 possible health states [16].
Using the US scoring function EQ-5D index scores
range from -0.11 (all-worst health state, worse than
dead), to 0.00 (dead) to 1.00 (perfect health) [36]. The
scoring function was estimated using time trade off
scores from a representative sample of the community-
dwelling US population. Changes of 0.10 or more in
EQ-5D index are considered clinically important.
The Hospital Anxiety and Depression Scale (HADS)
Mental health was assessed using the HADS [37]. HADS
is a self-complete mental health measure. The scale con-
sists of 14 items, 7 of which assess anxiety and 7 which
assess depression. Each item is on a four point scale and
the scores are added to give a total ranging from 0 to
21 for anxiety and 0 to 21 for depression. Higher scores
indicate higher severity of anxiety or depression. A cut-
point of 8 or 9 indicates mild burden for the two scales;
11 or 12 indicates severe [37]. HADS uses a one week
recall period. HADS has been used to measure anxiety
and depression in community screening and clinical
research.
Patient sociodemographic characteristics
At the first study visit (baseline assessment) the patients
completed a brief sociodemographic questionnaire. The
purpose was to provide a description of sociodemo-
graphic characteristics of this patient population. Items
included age, gender, level of education, and employ-
ment status.
Chronic conditions
Patients were asked whether they have been diagnosed
with any of the following conditions: arthritis or rheu-
matism, high blood pressure, asthma, chronic bronchitis
or emphysema, diabetes, epilepsy, effects on stroke
(paralysis or speech problems), paralysis, partial or com-
plete, other than the effects of a stroke, urinary inconti-
nence, difficulty controlling bowels, Alzheimer disease
or any other dementia, osteoporosis or brittle bones,
cataracts, glaucoma, stomach or intestinal ulcers, kidney
failure or disease, Crohn disease or colitis(bowel disor-
der), thyroid condition, developmental delay, schizo-
phrenia, depression, psychosis or other mental illness,
cancer. The number of chronic conditions was calcu-
lated for each patient.
Pulmonary Function
Patients’ medical records were reviewed to obtain the
6-minute walk test (6MWT) scores and the forced
expiratory volume, FEV1 percentage predicted, closest in
time to the date at which the patient enrolled in the
study. The cut-off point for FEV1 %predicted was ± 3
days of when HRQL was assessed; for the 6MWT the
cut-off was ± 5 days.
Formulation of a priori hypotheses
Seven out of the ten authors independently indicated
the direction and degree of expected association among
the measures in order to assess convergent and discri-
minant validity. Each author specified 90 ap r i o r i
hypotheses, of which 52 tested convergent and 38 discri-
minant validity. Ap r i o r ihypotheses were specified by
members of a multi-disciplinary team of clinicians that
included pulmunologists, nurses, a pharmacist and a
dietitian. All these predictions were compiled and a con-
sensus was reached for each of the 90 hypotheses by
endorsement of a proposed consensus set of hypotheses.
To classify the degree of association, we used the
scheme provided by Cohen (1988) [38] negligible (<0.1),
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large (>0.5).
To test convergent validity, we expected that patients
with a higher ambulation score to walk further in the
6MWT and to display a higher FEV1%pred score. Also,
HUI3 pain that covers activity disruption due to pain
was expected to be moderately and negatively correlated
with 6MWT, as patients experiencing pain and discom-
fort would have difficulty walking. Furthermore, HUI3
emotion focuses on happiness versus depression and
was expected to be largely correlated to HADS depres-
sion score.
Discriminative validity was demonstrated through test-
ing ap r i o r ihypotheses in situations in which we
expected to find a negligible correlation between the
measures. For instance, because vision is not expected
to be related to the pulmonary function, we expected
HUI3 vision to be negligibly correlated with FEV1%
pred. Similarly, marital status was expected to be negli-
gibly correlated with HUI3 cognition.
To assess the known-groups comparisons, we expected
that pre-transplant patients with symptoms such as fati-
gue and breathing limitations would experience limited
ambulation, thus displaying lower HUI3 ambulation than
post-transplant subjects. Also, pre-transplant patients
(waiting for transplant) would display lower HUI3 pain
scores (more pain) than post-transplant patients. At end-
stage lung disease some patients (pulmonary fibrosis and
arterial hypertension) suffer pleureitic chest pain. Other
pre-transplant patients (chronic obstructive pulmonary
disease) use the accessory breathing muscles which leads
to back and thoraxic cage pain. Also it was expected that
post-transplant subjects would report higher overall
HUI3 than pre-transplant patients.
Statistical analyses
The statistical analyses were conducted by one of the
authors who was not involved in the formulation of the
a priori hypotheses. Pearson correlations were estimated
for continuous variables; Spearman’s Rho test was used
for categorical variables, and unweighted kappa was cal-
culated to assess agreement between the predicted and
observed degrees of association. Agreement is inter-
preted following the scheme proposed by Altman [39] <
0.20, poor; 0.21-0.40, fair; 0.41-0.60, moderate; 0.61-0.80,
good; 0.81-1.00, very good. Student’st - t e s t sw e r ep e r -
formed to assess the known-group comparisons.
The statistical analyses were computed using SPSS
version 15.0 [40].
Results
The study was carried out between July 2005 and April
2007. During this period, 216 patients were invited to
participate. Three pre-transplant patients refused. Out of
the 213 enrolled patients, 103 were pre-transplant (52%
female) and 110 were post-transplant patients (46%
female). Table 1 presents the baseline demographic and
clinical characteristics for the 213 patients. Patients had a
mean age of 53 years with a range from 18 to 73 years.
Most of the patients had finished high school and were
on disability. Thirty one percent of the pre-transplant
patients rated their general health as poor versus four
percent in the post-transplant group. Similarly, fourteen
percent of the pre-transplant patients rated their general
health as good versus thirty eight percent in the post-
transplant group. The most common chronic conditions
were osteoporosis, arthritis, hypertension and diabetes.
The most common underlying diagnoses were chronic
obstructive pulmonary disease (COPD) and idiopathic
pulmonary fibrosis (IPF). These results are consistent
with the distribution of causes for lung transplantation
by country [41]. At enrollment in the study the mean
time waiting for transplant was 81 weeks (range from 1
to 158 weeks) for the pre-transplant group and the mean
time since transplant was 136 weeks (range 3 to 960
weeks) for the post-transplant group.
The age-matched (matched to the age distribution of
the patients) Canadian HUI3 norm for men is 0.89 and
0.90 for women, both indicating mild disability [10].
T h em e a nH U I 3o v e r a l ls c o r eo f0 . 6 3f o rt h ep a t i e n t s
indicates moderate to severe disability (see Table 2).
Overall scores ranged from 0.001 to 1.00. HUI3 pain
and HUI3 ambulation (0.80 and 0.78, respectively) were
the most severely affected attributes (see Table 2). The
number of chronic conditions ranged from 0 to 10, con-
sistent with the severity captured by the overall HUI3
score (see Table 2). The functional status of the patients
assessed by the mean 6MWT was moderate [42] 448
meters (SD 173 meters). Also, a mean percentage of
predicted FEV1 of 54 (SD 27.4) showed moderate [43]
chronic airflow impairment. These results are consistent
with the severity captured by the overall HUI3 score
(see Table 2).
Using the known-group approach, we expected the
pre-transplant patients to have lower overall HUI3,
and lower HUI3 ambulation and HUI3 pain scores
than post-transplant patients. Differences between pre-
and post-transplant in overall, ambulation and pain
were statistically significant and clinically important
(see Table 2).
The observed correlations are reported in Table 3.
Twelve out of the 52 hypotheses testing convergent valid-
ity and 5 out of the 38 testing discriminant validity were
not confirmed. Of the ninety predictions made, forty
three were correct but in 31 the correlation was slightly
lower than predicted and in 7 was much higher than pre-
dicted. The correlation between HUI3 overall score and
EQ-5D index was large (p = 0.001). HUI3 ambulation
Santana et al. Health and Quality of Life Outcomes 2010, 8:110
http://www.hqlo.com/content/8/1/110
Page 4 of 10Table 1 Demographic and clinical characteristics of the patients at baseline
Pre-transplant N = 103 Post-transplant
N = 110
Mean Age (SD) 54 (12.55) 53 (12.93)
Gender (%)
Female 55 44
Male 45 56
Race/Ethnicity (%)
White 98 92
American Indian 2 3
East Indian 0 2
Asian 0 1
Black 0 1
Marital Status (%)
Married 47 53
Single 50 50
Divorced 68 32
Other 46 55
Education (%)
High school 46 54
College 60 40
University 32 68
Employment (%)
Working 15 18
Unemployed 16 13
Retired 21 22
Disability 48 47
General Health (%)
Excellent 1 6
Very Good 14 38
Good 22 38
Fair 32 14
Poor 31 4
Chronic Conditions (%)
Arthritis 20 15
Osteoporosis 24 33
Hypertension 26 31
Diabetes 11 18
Other 9 3
Co-morbidities (%)
Chronic Obstructive Pulmonary Disease 43 41
Pulmonary Fibrosis 29 27
Pulmonary Arterial Hypertension
Cystic Fibrosis
10
15
11
19
Other 3 2
Mean Number of Chronic conditions (SD) 2.00 (1.74) 1.48 (1.56)
Mean Six Minute Walk test, in meters (SD) 357 (134) 548 (155)
Mean FEV1% pred* (SD) 39.20 (21.63) 67.10 (25.19)
Mean time since transplantation (weeks) 136 (range 3-960)
SD = Standard Deviation; *FEV1%pred = Predicted Forced Expiratory Volume in 1 second.
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(p = 0.001). Correlations between EQ-5D and HUI3
vision, hearing, speech, dexterity and cognition were neg-
ligible (p > 0.05). HUI3 emotion correlated moderately
with HADS anxiety (p = 0.001) and HADS depression
(p = 0.001). Correlation between HUI3 ambulation and
6MWT was large (p = 0.001). Also, there was a small cor-
relation between HUI3 pain and the 6MWT (p = 0.002).
As expected, marital status and HUI3 ambulation did not
correlate (p = 0.31). Also, HUI3 dexterity did not corre-
late with FEV1 (p = 0.36).
The accuracy of the ap r i o r ihypotheses is reported in
Table 4. The degree of agreement between ap r i o r i
hypotheses and observed correlations is reported in
Table 5. In 48% of the cases (43 out of 90) the predic-
tions were correct. In 42% of the cases predictions were
off by one category. A priori predictions were off by two
categories in 10% of the cases. The chance-corrected
agreement measured by unweighted Kappa statistics
was 0.25 (p = 0.0001), indicating fair chance-corrected
agreement between the observed and the predicted
associations.
Table 2 Description of patients HRQL
HRQL
Measures
Pre-transplant
Mean ± SD
Post-transplant
Mean ± SD
Difference between mean scores for post- and -pre-transplant patients
HUI3 vision 0.94 ± 0.12 0.92 ± 0.12 - 0.02
HUI3 hearing 0.94 ± 0.20 0.96 ± 0.17 0.02
HUI3 speech 0.99 ± 0.07 0.97 ± 0.15 0.02
HUI3 ambulation 0.66 ± 0.28 0.89 ± 0.19 0.23*
†
HUI3 dexterity 0.99 ± 0.02 0.97 ± 0.10 0.02*
HUI3 emotion 0.93 ± 0.10 0.94 ± 0.12 0.01
HUI3 cognition 0.93 ± 0.10 0.94 ± 0.12 0.01
HUI3 pain 0.76 ± 0.26 0.84 ± 0.17 0.08*
†
HUI3 overall 0.56 ± 0.26 0.69 ± 0.25 0.13*
†
EQ-5D index 0.71 ± 0.17 0.81 ± 0.15 0.10*
†
HADS anxiety 6.83 ± 3.44 5.42 ± 3.57 1.41*
HADS depression 5.82 ± 2.84 3.34 ± 3.30 2.48*
* Statistically significant (p < 0.05); †clinically important difference.
Table 3 Observed correlations
EQ-5D index HADS anxiety HADS depression 6MWT FEV1% pred NCC Age Gender Marital
Status
Transplant
Status
HUI3 overall 0.50 -0.43 -0.55 0.35 0.25 -0.20 -0.13 0.15 0.03 0.25
HUI3
vision
0.04* -0.06* -0.06* 0.01* 0.02* -0.02* 0.20 0.12* 0.01* 0.05*
HUI3
hearing
0.08* -0.11* -0.20 0.08* 0.11* 0.07* 0.15 0.02* 0.00* 0.03*
HUI3
speech
0.02* -0.24 -0.13* 0.05* 0.02* -0.01* 0.01 0.00* 0.02* 0.07*
HUI3
ambulation
0.40 -0.24 -0.50 0.59 0.36 -0.19 -0.15* 0.16* 0.00* 0.43
HUI3
dexterity
0.02* 0.11* 0.05* 0.05* 0.06* 0.13 -0.10* 0.03* 0.05* 0.17
HUI3
emotion
0.12 -0.40 -0.43 -0.08* 0.08* -0.01* 0.03* 0.02* 0.06* 0.01*
HUI3
cognition
0.08* -0.25 -0.19 -0.02* 0.01* -0.08* 0.12* 0.11* 0.08* 0.08*
HUI3
pain
0.44 -0.23 -0.26 0.17 0.09* -0.10* 0.03* 0.02* 0.03* 0.17
6MWT: Six-minute Walk test; FEV1: Percentage predicted Forced Expiratory Volume in 1 second; NCC: Number of Chronic Conditions;
Transplant Status: pre- or post-transplant.
* Non-significant correlations.
Bold: test of convergent validity; unbold: test for discriminant validity.
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This study is the first to explore the cross-sectional con-
struct validity of the HUI3 in lung transplantation. In
particular, 90 hypotheses concerning the associations
between HUI3 single attribute utility scores and overall
HUI3 utility scores and various measures of health sta-
tus such as pulmonary function (FEV1% predicted) and
t h es i x - m i n u t ew a l kt e s tw e r ee x a m i n e d .O ft h e9 0
hypotheses 43 predictions were exact, 40 were slightly
lower than predicted and 7 were slighted higher than
predicted. Overall, the results provide evidence support-
ing the cross-sectional construct validity of HUI3 in
lung transplantation.
Our results are similar to results in previous studies
investigating construct validity [22,44,45]. Two of the
studies included asthmatic children and their caregivers,
reporting success rates (% of ap r i o r ihypotheses that
were confirmed) of 55.6% and 50%, respectively. The
third study included high-risk primary-care patients and
reported a success rate of 50%. However, in 2004
Blanchard et al [24] conducted a construct validity study
in patients undergoing elective total hip arthroplasty,
reporting a success rate of 75%.
Because the HUI3 and the EQ-5D belong to the same
group of measures, clinicians expected the correlations
between the HUI3 single attributes scores and the EQ-
5D to be higher. Clinicians overestimated the correla-
tions between the EQ-5D and the HUI3 in most of the
attributes except for HUI3 cognition. However the cor-
relation between the overall HUI3 and EQ-5D scores
was large and the prediction was confirmed. A possible
explanation for the pattern of results is that the EQ-5D
is a cruder measure than the HUI3. HUI3 includes eight
attributes with five or six levels each whereas EQ-5D
includes four attributes with three levels each. This dif-
ference in depth and breadth between the measures
allows the HUI3 to provide more descriptive power for
highly impaired states. Luo et al [22,25] noted that EQ-
5D was not able to differentiate health status at higher
levels of functioning.
The correlation between HUI3 emotion and the
HADS anxiety and depression scores was medium. The
team expected a higher degree of association for both.
The prediction was off by one category. Asakawa et al
[30] assessed the construct validity of the HUI3 in Alz-
heimer disease, arthritis and cataracts. The authors
Table 4 A priori and observed associations
EQ-5D index HADS anxiety HADS depression 6MWT FEV1% pred NCC Age Gender Marital
Status
Transplant
Status
HUI3 overall LM M/L M M/S L/S M/S S S/N M
HUI3
vision
M/N M/N S/N S/N NN M/S N/S NN
HUI3
hearing
M/N M/S M/S N N/S N M/S NN N
HUI3
speech
S/N N/S SN N N N N N N
HUI3
ambulation
L/M M/S LL L/M M/S M/S N/S N L/M
HUI3
dexterity
M/N M/S M/N NN N/S S N N N/S
HUI3
emotion
L/S L/M L/M S/N M/N S/N S/N NN N
HUI3
cognition
N M/S M/S NN N S S N N
HUI3
pain
L/M M/S M/S M/S M/N M/S S/N NN M/S
6MWT: Six-minute Walk test; FEV1% pred: Percentage predicted Forced Expiratory Volume in 1 second; NCC: Number of Chronic Conditions.
N = negligible degree of association, correlation < 0.1; S = Small degree of association, correlation 0.1 to < 0.30; M = medium degree of association, correlation
0.30 to < 0.5; L = large degree of association, correlation ≥ 0.5.
Bold = a perfect match between a priori and observed; italics = a difference of one category in which a priori < observed;
bold italic = a difference of one category in which a priori > observed; underline = a difference of two categories in which a priori < observed; double underline =
a difference of two category in which a priori > observed;
Table 5 Accuracy of a priori predictions
N = 90 %
Exact 43 48
Off by 1 category 38 42
a priori > observed 31
a priori < observed 7
Off by 2 category 9 10
a priori > observed 9
a priori < observed 0
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emotion and emotional problems associated to arthritis
and cataracts. A possible explanation for our findings is
that the HUI3 is a generic measure that focuses on hap-
piness versus depression whereas HADS depression
scale is based on anhedonia or the state of reduced abil-
ity to experience pleasure [37].
The degree of association expected by clinicians
between 6MWT and HUI3 ambulation was correct.
However, clinicians were expecting to find a higher
degree of association between FEV1% predicted and
HUI3 ambulation. The prediction was off by one cate-
gory. Past studies have addressed the discrepancy in the
correlation between FEV1% predicted and HRQL mea-
sures [42,46,47]. Poor association between clinical para-
meters and HRQL scores may be explained by the fact
that objectively measurement doesn’t reflect patients’
perceptions, suggesting that HRQL information is neces-
sary to complement patients’ clinical care.
Clinicians were expecting to find a higher correlation
between age and cognition. It would be interesting in
future studies to examine the degree of association
between age and HUI3 cognition in different clinical
and age groups. It could be that in this group the major
determinants of cognitive status are co-morbidities and
degree of severity of their lung disease and other
chronic conditions, rather than the age of the patient.
Clinicians’ expectations about the degree of associa-
tion between HUI3 scores and transplant status were
confirmed for six out of nine predictions. Predictions
for HUI3 ambulation and HUI3 pain exceeded the
observed correlation slightly. A possible explanation for
the overestimation may be due to the high number (n =
67) of patients who had been transplanted more than a
year before enrolling in the study.
When patients were stratified by transplant status
(pre- and post-transplant) to examine known-group
validity, pre-transplant patients reported lower mean
overall HUI3 (0.56) than post-transplant (0.69) patients.
The difference was statistically significant (p = 0.005)
and clinically important (see Table 2). As expected,
HUI3 ambulation and pain were the most affected attri-
butes before transplantation and were much higher in
the post-transplant group. The differences were statisti-
cally significant (HUI3 ambulation, p = 0.01; HUI3 pain,
p = 0.02) and clinically important (see Table 2). The
present study corroborated the finding in a previous
study [10] confirming that HUI3 ambulation and HUI3
pain were the most affected attributes before transplan-
tation and that overall HUI3 scores were higher in post-
transplant patients.
In this study, most of the predictions were confirmed.
Over-prediction of the degree of association by one
category was more frequent than under-prediction by
one category. This pattern was also seen in a study con-
ducted by Feeny et al 2009 [32]. Feeny et al. noted that
the success in predicting the degree of associations
depends on the validity of the measures used in the
study, usefulness of the underlying theory used to derive
the hypotheses and knowledge of the measures and
study subjects by those who formulate the ap r i o r i
predictions.
In the context of this study, the clinicians who formu-
lated the a priori predictions were highly familiar with
lung transplantation patients in general and the charac-
teristics of the patients enrolled in the study in particu-
lar. These experienced clinicians were also very familiar
with standard clinical measures such as the 6MWT and
the FEV1% predicted. Many of the clinicians involved in
the study were actively using HUI3 in the management
of these patients so probably were knowledgeable about
that measure, although not knowledgeable about the
EQ-5D. The clinicians while knowledgeable about men-
tal health issues were probably not very familiar with
the HADS. As noted above the success in confirming a
priori predictions in this study is consistent with the
success rates noted in a number of previous studies.
The nature of the theory used to inform a priori predic-
t i o n si nt h i ss t u d yw a sf o rt h em o s tp a r ti m p l i c i ta n d
based on intuitive clinical reasoning and experience. It
is possible that the use of a more rigorous and explicit
underlying theory would have improved the success rate
in predicting the observed degree of associations.
The increasing demands of lung transplantation on
health care systems have stimulated much interest in the
cost effectiveness of health care interventions in this
patient population. Lung transplantation is effective but
expensive technology, having a valid utility measure that
allow for cost-effectiveness comparison is important. In
this study, HUI3 shown to be valid and able to capture
both the burden of lung disease before transplantation and
the higher levels of health status and HRQL enjoyed by
patients after transplantation. Further cost-effectiveness
analyses using HUI3 is warranted.
There are a number of study limitations to consider
when interpreting these findings. First, patients with cog-
nitive problems and non-English speakers were excluded,
limiting generalizability. Secondly, most of the participants
were White and recruited at a tertiary-care institution
therefore results may not be generalizable to other set-
tings. However, the underlying distribution of causes for
lung failure is similar to most cohorts seen internationally.
Furthermore, the a priori hypotheses were performed at
one point in time, at baseline. Because this is the first
study to explore the construct validity of the HUI3 in lung
transplantation, replication of the study is warranted in
future studies. Although responsiveness of the HUI3 has
been previously assessed [48,49] the present study did not
Santana et al. Health and Quality of Life Outcomes 2010, 8:110
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tion. A further investigation of the longitudinal construct
validity of the HUI3 in lung transplantation is warranted.
Conclusion
T h i si st h ef i r s ts t u d yt h a tp r o v i d e se v i d e n c eo ft h e
cross-sectional construct validity of HUI3 in lung trans-
plantation. Results indicate that the HUI3 was able to
capture both the burden of lung disease before trans-
plantation and the higher levels of health status and
HRQL enjoyed by patients after transplantation.
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